Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction by E. F. Muslimova, V. A. Korepanov, T. Yu. Rebrova, S. L. Andreev, S. A. Afanasiev

“…Aim. To evaluate β-adrenergic reactivity of erythrocyte membranes (β-ARM) depending on clinical parameters in patients with heart failure (HF) with preserved and reduced ejection fraction (EF), who had prior myocardial infarction.Material and methods. …”
Get full text

Beta-adrenergic reactivity of erythrocyte membranes in various phenotypes of uncontrolled hypertension by M. A. Manukyan, A. Yu. Falkovskaya, V. F. Mordovin, I. V. Zyubanova, V. A. Lichikaki, E. I. Solonskaya, A. A. Vtorushina, S. A. Khunkhinova, I. A. Skomkina, V. V. Rudenko, T. Yu. Rebrova, E. F. Muslimova, S. A. Afanasyev

Subjects: “…β-adrenergic reactivity of erythrocyte membranes…”
Get full text

NEBIVOLOL – ESPECIAL BETA-ADRENOBLOCKER by T. Műnzel, T. Gori

“…The somewhat-different β-adrenergic receptor blocker was initially published in J Am Coll Cardiol 2009;54:1491–9 © 2009 by the American College of Cardiology Foundation.…”
Get full text

Association of β1- and β2-adrenergic receptor gene polymorphisms with the risk of heart failure in patients with type 2 diabetes mellitus by N.M. Kulaiets

“…Gene polymorphisms of β1- and β2-adrenergic receptors (β1- and β2-AR) probably play an important role in the occurrence, progression of HF and the formation of response to therapy with β-adrenergic blockers. Conducting a comprehensive analysis can add arguments in favor of a cause-and-effect relationship between polymorphisms and disease phenotypes. …”
Get full text

Water-soluble vidarabine derivatives alleviate catecholamine-induced heart failure and arrhythmia without impairing cardiac function in mice. by Kenji Suita, Yoshio Hayakawa, Yujiro Hoshino, Wenqian Cai, Reiko Kurotani, Yoshiki Ohnuki, Yasumasa Mototani, Yoshihiro Ishikawa, Satoshi Okumura

“…However, despite gains in the treatment of HF with angiotensin and β-adrenergic receptor (β-AR) blockers, some patients do not tolerate β-AR blocking therapy to inhibit cardiac function and contract the respiratory tract. …”
Get full text

Endocrine disruptors as promoters of biosphere carcinogenic background by G. A. Belitsky, K. I. Kirsanov, E. A. Lesovaya, E. M. Zhidkova, I. A. Khitrovo, M. G. Yakubovskaya

“…In addition, they activate alternative proliferation signaling pathways by activating g-proteincoupled receptors, estrogen-bound eRRγ or/and β-adrenergic receptors. The main mechanism of action of endocrine disruptors is the induction of epigenetic modifications, in particular, methylation/demethylation of cpg dNa islands, histone modifications and changes in expression of non-coding RNa. since the effects of endocrine disruptors are nonlinear, they can be caused by concentrations corresponding to the real content in the biosphere and detected in the umbilical blood and breast milk. …”
Get full text